目的 研究丹參酮ⅡA磺酸鈉聯(lián)合重組人腦利鈉肽治療心肌梗死的臨床療效、心功能改善情況和預(yù)后。方法 選擇2015年1月-2017年12月銅川市人民醫(yī)院收治的158例心肌梗死患者作為研究對(duì)象，將患者隨機(jī)分為兩組，每組各79例。對(duì)照組iv重組人腦利鈉肽，觀察組在對(duì)照組的基礎(chǔ)上靜脈滴注丹參酮ⅡA磺酸鈉注射液，兩組均治療14 d。觀察兩組患者的臨床療效，同時(shí)比較兩組治療前后的心功能指標(biāo)、血清學(xué)指標(biāo)和預(yù)后情況。結(jié)果 治療后，觀察組的總有效率為91.14%，明顯高于對(duì)照組的77.21%（P<0.05）。治療后，兩組患者左心室射血分?jǐn)?shù)（LVEF）均明顯升高，左心室舒張末期內(nèi)徑（LVDd）及左心室后壁厚度（LVPWT）明顯降低（P<0.05）；且觀察組心功能指標(biāo)顯著優(yōu)于對(duì)照組（P<0.05）。治療后，兩組的超氧化物歧化酶（SOD）水平明顯升高，心肌肌鈣蛋白（cTnI）、肌酸激酶同工酶（CK-MB）及內(nèi)皮素-1（ET-1）水平均顯著降低（P<0.05）；且觀察組血清學(xué)指標(biāo)水平明顯優(yōu)于對(duì)照組（P<0.05）。治療后，觀察組再梗死、心源性休克、心律失常以及心絞痛的發(fā)生率均明顯低于對(duì)照組（P<0.05）。結(jié)論 丹參酮ⅡA磺酸鈉聯(lián)合重組人腦利鈉肽治療心肌梗死的療效顯著，有助于改善患者的心功能指標(biāo)，且預(yù)后效果較為滿(mǎn)意。

Objective To study the effect of sodium tanshinone Ⅱ A sulfonate combined with recombinant human brain natriuretic peptide in treatment of myocardial infarction, improvement of cardiac function and prognosis. Methods 158 cases of patients with myocardial infarction in Tongchuan People's Hospital from January 2015 to December 2017 were randomly divided into two groups, each group had 79 cases. The control group was intravenously injected with recombinant human brain natriuretic peptide, and the observation group was given intravenous drip of sodium tanshinone Ⅱ A sulfonate, Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and cardiac function indexes, serological indexes, and prognosis in two groups before and after treatment were compared. Results After treatment, the effective rate of the observation group was 91.14%, which was significantly higher than 77.21% in the control group (P<0.05). After treatment, LVEF in two groups were significantly increased, but the LVDd and LVPWT were decreased (P<0.05), and cardiac function indexes in the observation group were better than those in the control group (P<0.05). After treatment, the SOD level in the two groups were increased significantly, but the levels of cTnI, CK-MB and ET-1 in the two groups were significantly decreased (P<0.05), and serological indexes in the observation group were better than those in the control group (P<0.05). The incidence of re infarction, cardiogenic shock, arrhythmia and angina pectoris in the observation group were significantly lower than control group (P<0.05). Conclusions The effect of sodium tanshinone Ⅱ A sulfonate combined with recombinant human brain natriuretic peptide in treatment of myocardial infarction is curative, and it is helpful to improve the cardiac function of the patients, and the prognosis is satisfactory.